about
Multidimensional profiling platforms reveal metabolic dysregulation caused by organophosphorus pesticidesThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsTomatoes, lysophosphatidic acid, and the small intestine: new pieces in the puzzle of apolipoprotein mimetic peptides?Lysophosphatidic Acid Is Associated with Atherosclerotic Plaque Instability by Regulating NF-κB Dependent Matrix Metalloproteinase-9 Expression via LPA2 in Macrophages.Diet-induced obesity links to ER positive breast cancer progression via LPA/PKD-1-CD36 signaling-mediated microvascular remodeling.Mechanosensitive PPAP2B Regulates Endothelial Responses to Atherorelevant Hemodynamic Forces.US28 is a potent activator of phospholipase C during HCMV infection of clinically relevant target cellsGenetic and environmental risk factors for atherosclerosis regulate transcription of phosphatase and actin regulating gene PHACTR1.Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.Lipid-induced epigenomic changes in human macrophages identify a coronary artery disease-associated variant that regulates PPAP2B Expression through Altered C/EBP-beta binding.Small lipidated anti-obesity compounds derived from neuromedin U.Deficiency or inhibition of lysophosphatidic acid receptor 1 protects against hyperoxia-induced lung injury in neonatal rats.PPAR γ Networks in Cell Signaling: Update and Impact of Cyclic Phosphatidic Acid.Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acidLysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase.The effects of aspirin and fish oil consumption on lysophosphatidylcholines and lysophosphatidic acids and their correlates with platelet aggregation in adults with diabetes mellitus.G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease.Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation.Bioactive lipids in aortic valve stenosis-a possible link to atherosclerosis?Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient miceQuantitation of phosphatidic acid and lysophosphatidic acid molecular species using hydrophilic interaction liquid chromatography coupled to electrospray ionization high resolution mass spectrometry.Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease.LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques relies on a PLD2-CD36 functional interdependence.Autotaxin in Pathophysiology and Pulmonary Fibrosis.
P2860
Q28387124-7FB83E7D-CC3B-4127-AA34-29E499D11260Q30486707-789DA92D-506C-4178-8F68-23CED518F9F5Q33356762-B1D483D8-23B6-402F-A9A2-BCA8D168FC21Q33607215-2894D2A8-CF45-473F-B048-CFC953D5BEA5Q33618393-6A36E83A-7950-4E00-96EE-1DEAA20D38D3Q34478873-57A13AEA-0072-4A19-918B-F0D8A23C6C9DQ34500430-6EC1DAA0-AFA1-4885-AD7E-4EC895D79DF5Q34526953-28C76856-2188-488E-B0E2-598A9F7DEAEFQ35217048-B686F466-EF68-4636-BF54-40744A5D8195Q35250745-C8B8A6E6-868E-428C-9BF9-415B42FE89AFQ35708420-2E8FD685-AF72-49D0-BE55-F89FF9880E4DQ36535430-928139B1-DACC-4262-A991-5F636C39DE7FQ36637912-BB0ABB53-5205-4F77-BE84-35B45663512AQ37305392-A32F9B7A-6E38-4357-B804-C7D724F03296Q37503698-5501FE99-21C2-400E-8D53-4CC61770EDA3Q37612293-BD9A5D7D-DB90-4F58-8F56-4C372F6D8C2DQ38389922-F16370BC-FBDD-48FD-96A0-7A9BD0085AB2Q39741685-9013C882-2FCD-45BA-BB05-6597FA24F741Q40062794-12D418BF-6939-4887-BBBA-A8B5340148E6Q42363985-B98D864F-7C30-44AF-98AD-62A0D178E401Q43629218-E4741987-AA17-4B03-B59A-17D2FEB97CD3Q45944920-DD1149DA-AA5A-4AAF-BE4C-59D1AAAA6303Q46228136-13F869B0-D4FB-4B39-B633-07894F93019DQ52587771-7EDE75A1-C18D-48C7-8B47-1FCB3165A808Q55420502-D473B53D-8A6A-43A6-86E8-4FC4C9D3A434
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Lysophosphatidic acid in atherosclerotic diseases
@ast
Lysophosphatidic acid in atherosclerotic diseases
@en
Lysophosphatidic acid in atherosclerotic diseases
@nl
type
label
Lysophosphatidic acid in atherosclerotic diseases
@ast
Lysophosphatidic acid in atherosclerotic diseases
@en
Lysophosphatidic acid in atherosclerotic diseases
@nl
prefLabel
Lysophosphatidic acid in atherosclerotic diseases
@ast
Lysophosphatidic acid in atherosclerotic diseases
@en
Lysophosphatidic acid in atherosclerotic diseases
@nl
P2860
P1476
Lysophosphatidic acid in atherosclerotic diseases
@en
P2093
Wolfgang Siess
P2860
P304
P356
10.1111/J.1476-5381.2012.02021.X
P407
P577
2012-10-01T00:00:00Z